Security Asset Management Invests $74,000 in Celgene Co. (CELG)

Security Asset Management purchased a new position in Celgene Co. (NASDAQ:CELG) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 1,153 shares of the biopharmaceutical company’s stock, valued at approximately $74,000.

Several other large investors also recently bought and sold shares of CELG. Sompo Japan Nipponkoa Asset Management CO. LTD. raised its stake in Celgene by 2.3% during the 4th quarter. Sompo Japan Nipponkoa Asset Management CO. LTD. now owns 80,750 shares of the biopharmaceutical company’s stock worth $5,175,000 after buying an additional 1,850 shares during the period. Malaga Cove Capital LLC raised its stake in shares of Celgene by 1.6% in the 4th quarter. Malaga Cove Capital LLC now owns 8,887 shares of the biopharmaceutical company’s stock valued at $566,000 after purchasing an additional 143 shares during the period. Brave Asset Management Inc. raised its stake in shares of Celgene by 20.0% in the 4th quarter. Brave Asset Management Inc. now owns 21,665 shares of the biopharmaceutical company’s stock valued at $1,389,000 after purchasing an additional 3,610 shares during the period. LS Investment Advisors LLC raised its stake in shares of Celgene by 17.2% in the 4th quarter. LS Investment Advisors LLC now owns 22,738 shares of the biopharmaceutical company’s stock valued at $1,457,000 after purchasing an additional 3,335 shares during the period. Finally, Algert Global LLC acquired a new stake in shares of Celgene in the 4th quarter valued at about $345,000. Institutional investors and hedge funds own 75.15% of the company’s stock.

NASDAQ:CELG opened at $89.87 on Tuesday. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13. The stock has a market capitalization of $63.00 billion, a P/E ratio of 11.81, a P/E/G ratio of 0.41 and a beta of 1.72. Celgene Co. has a 52-week low of $58.59 and a 52-week high of $97.43.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.07. The business had revenue of $4.04 billion for the quarter, compared to the consensus estimate of $3.98 billion. Celgene had a return on equity of 125.35% and a net margin of 26.48%. During the same quarter in the previous year, the business earned $2.00 earnings per share. On average, analysts anticipate that Celgene Co. will post 10.01 earnings per share for the current year.

Several research firms have issued reports on CELG. Mizuho set a $117.00 price target on Celgene and gave the company a “buy” rating in a research note on Tuesday, October 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $100.00 price target on shares of Celgene in a research note on Thursday, January 3rd. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 5th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a research note on Thursday, October 25th. Finally, Goldman Sachs Group raised Celgene from a “sell” rating to a “neutral” rating and lifted their price target for the company from $71.00 to $88.00 in a research note on Thursday, January 3rd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $109.29.

In related news, Director James J. Loughlin sold 23,466 shares of Celgene stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $87.29, for a total value of $2,048,347.14. Following the sale, the director now owns 62,102 shares of the company’s stock, valued at $5,420,883.58. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.39% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “Security Asset Management Invests $74,000 in Celgene Co. (CELG)” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2019/02/12/security-asset-management-invests-74000-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: Liquidity

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply